← Back to Analyst Consensus 
MBRX Buy
Moleculin Biotech, Inc.
Current Price —
Implied Upside —
Analysts 9
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (15 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 28, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Dec 11, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| Sep 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $4 | 44% |
| Aug 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $4 | 44% |
| Jun 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $4 | 44% |
| Mar 25, 2025 | Maxim Group | upgrade | Hold → Buy | $4 | 41% |
| Mar 25, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 24, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 3, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Nov 12, 2024 | Maxim Group | maintain | Buy → Buy | $8 | 41% |
| Apr 12, 2024 | Roth MKM | maintain | Buy → Buy | $40 | 52% |
| Mar 26, 2024 | Maxim Group | maintain | Buy → Buy | $20 | 41% |
| Dec 14, 2023 | HC Wainwright & Co. | initiate | — → Buy | $3 | 44% |
| Apr 18, 2023 | Roth MKM | maintain | — → Buy | $16 | 52% |
| Mar 24, 2023 | Oppenheimer | reiterate | — → Outperform | $5 | 52% |
Price Target Trend
May 12, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days